MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Levodopa(L-dopa)"

  • 2016 International Congress

    Levodopa impairs learning in healthy young adults: Implications for Parkinson’s disease

    P.A. MacDonald, A. Vo, K.N. Seergobin (London, ON, Canada)

    Objective: The objective was to investigate the effect of dopaminergic therapy on healthy young adults to test the dopamine overdose hypothesis. Background: Dopaminergic therapy improves…
  • 2016 International Congress

    Diurnal variation of levodopa plasma concentration in patients with Parkinson’s disease

    M. Nagai, M. Kubo, H. Iwaki, R. Ando, H. Yabe, N. Nishikawa, M. Nomoto (Ehime, Japan)

    Objective: We analyzed diurnal variation of levodopa plasma concentration in large number of patients with Parkinson's disease (PD) to clarify the pattern of diurnal variation.…
  • 2016 International Congress

    Subthalamic deep brain stimulation vs. intraduodenal levodopa infusion: A long-term retrospective comparative study

    A. Merola, A.J. Espay, A. Romagnolo, A. Bernardini, M. Rosso, K.J. Espay, L. Rizzi, M. Zibetti, M. Lanotte, L. Lopiano (Torino, Italy)

    Objective: To analyze the long-term retrospective data of patients treated with Levodopa/carbidopa intestinal gel infusion (LCIG) and subthalamic nucleus deep brain stimulation (STN-DBS) in two…
  • 2016 International Congress

    Status of NPF-QII after six years: Updates to the dataset

    F. Cubillos, E.C. Nelson, T. Simuni, C. Marras, M. Rafferty, T. Davis, P. Schmidt (Miami, FL, USA)

    Objective: To describe the status and recent findings from the National Parkinson Foundation's Quality Improvement Initiative (NPF-QII), an 8,179 subject observational clinical study conducted at…
  • 2016 International Congress

    Motor features and response to levodopa in Parkinson’s disease with normal olfactory function

    M. Rossi, A. Medina Escobar, A. Bril, P. Millar Vernetti, J.I. De Palo, D. Cerquetti, M. Merello (Buenos Aires, Argentina)

    Objective: The aim of this study was to evaluate motor features in the OFF and ON states and the acute levodopa response in Parkinson's disease…
  • 2016 International Congress

    Increased energy expenditure in early Parkinson’s disease during exercise

    T. Margaliot Kalifa, N. Ziv, H. Bergman, S. Nusair, D. Arkadir (Jerusalem, Israel)

    Objective: To measure both resting energy expenditure rate (REER) and energy expenditure during mild to moderate exercise in patients with early Parkinson's disease (PD) that…
  • 2016 International Congress

    Effectiveness of duodenal levodopa/carbidopa infusion gel (LCIG) therapy on the neuropsychiatric disturbances of advanced Parkinson’s disease (EDIS study)

    M.J. Catalan, P. Montero, J. Herreros, J.M. Arbelo, P. Martinez-Martin (Madrid, Spain)

    Objective: To evaluate the effectiveness of LCIG on neuropsychiatric disturbances in advanced Parkinson's disease (APD) patients. Background: Neuropsychiatric disorders are prevalent in PD and may…
  • 2016 International Congress

    Predicting medication reduction in Parkinson’s disease patients after deep brain stimulation

    S.A. Dodwell, C.E. Ashton, D.K. Simon, D. Tarsy, E. Papavassiliou, R. Alterman, L. Shih (Boston, MA, USA)

    Objective: To determine which factors predict medication reduction for Parkinson's disease (PD) patients after deep brain stimulation (DBS) of the bilateral subthalamic nucleus (STN). Background:…
  • 2016 International Congress

    A multi-centre European comparative survey of advanced therapies (infusion and deep brain stimulation) in Parkinson’s disease

    A.M. Rizos, P. Martinez-Martin, P. Reddy, M. Silverdale, K. Ashkan, A. Antonini, D. Calandrella, P. Odin, T. Henriksen, N. Bryndum, A. Glad, M.G. Kramberger, Z. Pirtošek, M. Trošt, T. van Laar, R. Katzenschlager, H.S. Dafsari, L. Timmermann, A. Storch, H. Reichmann, K. Ray Chaudhuri, On behalf of EUROPAR, The IPMDS Non-Motor PD Study Group (London, United Kingdom)

    Objective: To address comparative demographic and other variables for Parkinson's disease patients at baseline for infusion therapies (subcutaneous apomorphine (Apo), intrajejunal levodopa (IJLI)) and deep…
  • 2016 International Congress

    Clinical effect and dose conversion of rytary (numient) in 50 consecutive patients with PD motor fluctuations

    N. Chhabria, S.H. Isaacson (Boca Raton, FL, USA)

    Objective: To review the clinical use of a newer extended-release levodopa preparation in 50 consecutive patients with PD experiencing motor fluctuations on immediate-release levodopa. Background:…
  • « Previous Page
  • 1
  • …
  • 48
  • 49
  • 50
  • 51
  • 52
  • …
  • 57
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • An atypical and interesting feature of Parkinson´s disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley